Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

B Angus

Showing results (151-160 of 166) with videos related to

Pageof 17
Sort By:
Journal of Clinical Pathology|February 1, 1987
Practical value of genotypic analysis for diagnosing lymphoproliferative disordersN T O'Connor, K C Gatter, J S Wainscoat, et al.
The American Journal of Pathology|June 1, 1993
Association of Epstein-Barr virus with pediatric Hodgkin's diseaseA A Armstrong, F E Alexander, R P Paes, et al.
Oncogene|September 7, 1995
Determination of the prognostic value of cyclin D1 overexpression in breast cancerG G McIntosh, J J Anderson, I Milton, et al.
Leukemia|September 1, 1992
Criteria for the definition of Epstein-Barr virus association in Hodgkin's diseaseA A Armstrong, L M Weiss, A Gallagher, et al.
Hematological Oncology|January 1, 1989
Lomustine, vindesine and bleomycin (LVB) used in the treatment of relapsed advanced Hodgkin's disease. A prospective study on behalf of the East of Scotland and Newcastle Lymphoma Group (ESNLG)A L Lennard, S J Proctor, A A Dawson, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2002
A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III)S J Proctor, M Mackie, A Dawson, et al.
Leukemia & Lymphoma|November 17, 2006
The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trialP R A Taylor, J M White, R J Prescott, et al.
HIV Medicine|September 4, 2010
Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)S L Pett, C Carey, E Lin, et al.
The Journal of Pathology|September 1, 1996
Retinoblastoma protein in human breast carcinoma: immunohistochemical study using a new monoclonal antibody effective on routinely processed tissuesJ J Anderson, D G Tiniakos, G G McIntosh, et al.
The Journal of Biological Chemistry|April 5, 1990
Site-directed mutagenesis in human tissue-plasminogen activator. Distinguishing sites in the amino-terminal region required for full fibrinolytic activity and rapid clearance from the circulationT J Ahern, G E Morris, K M Barone, et al.
Pageof 17

Showing results (151-160 of 166) with videos related to

Sort By:
Pageof 17
Journal of Clinical Pathology|February 1, 1987
Practical value of genotypic analysis for diagnosing lymphoproliferative disordersN T O'Connor, K C Gatter, J S Wainscoat, et al.
The American Journal of Pathology|June 1, 1993
Association of Epstein-Barr virus with pediatric Hodgkin's diseaseA A Armstrong, F E Alexander, R P Paes, et al.
Oncogene|September 7, 1995
Determination of the prognostic value of cyclin D1 overexpression in breast cancerG G McIntosh, J J Anderson, I Milton, et al.
Leukemia|September 1, 1992
Criteria for the definition of Epstein-Barr virus association in Hodgkin's diseaseA A Armstrong, L M Weiss, A Gallagher, et al.
Hematological Oncology|January 1, 1989
Lomustine, vindesine and bleomycin (LVB) used in the treatment of relapsed advanced Hodgkin's disease. A prospective study on behalf of the East of Scotland and Newcastle Lymphoma Group (ESNLG)A L Lennard, S J Proctor, A A Dawson, et al.
European Journal of Cancer (Oxford, England : 1990)|April 9, 2002
A population-based study of intensive multi-agent chemotherapy with or without autotransplant for the highest risk Hodgkin's disease patients identified by the Scotland and Newcastle Lymphoma Group (SNLG) prognostic index. A Scotland and Newcastle Lymphoma Group study (SNLG HD III)S J Proctor, M Mackie, A Dawson, et al.
Leukemia & Lymphoma|November 17, 2006
The addition of oral idarubicin to a chlorambucil/dexamethasone combination has a significant impact on time to treatment failure but none on overall survival in patients with low grade non-Hodgkin's lymphoma: Results of the Scotland and Newcastle Lymphoma Group randomized NHL VIII trialP R A Taylor, J M White, R J Prescott, et al.
HIV Medicine|September 4, 2010
Predictors of bacterial pneumonia in Evaluation of Subcutaneous Interleukin-2 in a Randomized International Trial (ESPRIT)S L Pett, C Carey, E Lin, et al.
The Journal of Pathology|September 1, 1996
Retinoblastoma protein in human breast carcinoma: immunohistochemical study using a new monoclonal antibody effective on routinely processed tissuesJ J Anderson, D G Tiniakos, G G McIntosh, et al.
The Journal of Biological Chemistry|April 5, 1990
Site-directed mutagenesis in human tissue-plasminogen activator. Distinguishing sites in the amino-terminal region required for full fibrinolytic activity and rapid clearance from the circulationT J Ahern, G E Morris, K M Barone, et al.
Pageof 17